Repligen Corporation Common Stock vs Roundhill S&P 500 0DTE Covered Call Strategy ETF — how do they compare? Repligen Corporation Common Stock trades at $178.19 (market cap $11.14B), while Roundhill S&P 500 0DTE Covered Call Strategy ETF trades at $38.02 (market cap $330.26M). The key difference: Repligen Corporation Common Stock is far larger — about 33.7× Roundhill S&P 500 0DTE Covered Call Strategy ETF's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, Roundhill S&P 500 0DTE Covered Call Strategy ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Roundhill S&P 500 0DTE Covered Call Strategy ETF for 56 Days on average.
| RGEN | XDTE | |
|---|---|---|
Market Cap | $11.14B | $330.26M |
Volume | 1,259,263 | 54,618 |
Sector | Health | Income / Options Overlay |
52-Week High | $194.57 | $44.76 |
52-Week Low | $102.87 | $36.00 |
Typical Hold Time | 0 Days | 56 Days |
Enterprise Value | $11.02B | — |
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
XDTE (Roundhill S&P 500 0DTE Covered Call Strategy ETF) trades at $38.70 with no recent price movement. The technical picture appears bearish with moving averages signaling caution, while oscillators remain neutral. Recent news highlights concerns about the sustainability of XDTE's high yield strategy, with multiple articles questioning whether dividend payments represent true income or return of capital. The fund's weekly dividend payments range from $0.09 to $0.20, but analysts express skepticism about the underlying math.
The outlook for XDTE remains cautious as structural concerns about its covered call strategy persist. While the fund offers attractive weekly income, questions about yield sustainability and fee efficiency present significant risks. Investors should weigh the trade-offs between immediate income generation and potential long-term capital appreciation limitations in flat or rising markets.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →XDTE is an actively managed ETF that utilizes a synthetic covered call strategy on the S&P 500 Index using zero-days-to-expiration (0DTE) options. It seeks to provide high weekly income and overnight exposure to the index while mitigating some volatility through daily option premium harvesting.
Read more on XDTE →